CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing
Cash and cash equivalents of $83.5 million as of June 30, 2025
Company expects its cash and cash equivalents will continue to fund operations into 2027
PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2025, and reported on recent and upcoming business highlights.
“We remain focused on progressing our clinical pipeline — CTIM-76, a selective Claudin 6 (“CLDN6”) x CD3 bispecific antibody, and CT-95, an avidity enhanced mesothelin (“MSLN”) x CD3 bispecific antibody,” said Martin Lehr, CEO of Context. “We expect to share initial dose escalation data for the CTIM-76 trial in the second quarter of 2026 and for the CT-95 trial by mid-2026.”
“We also expect to complete necessary regulatory filings to support the initiation of a first-in-human trial for CT-202, a potential best-in-class Nectin-4 x CD3 bispecific antibody, in the second quarter of 2026,” Mr. Lehr continued. “With cash runway into 2027, we believe we are well-positioned to achieve our goal of advancing our portfolio of innovative T cell-engaging therapies for solid tumors.”
Second Quarter 2025 Highlights
Pipeline Updates
Corporate Updates and Presentations
Second Quarter 2025 Financial Results
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) our expectation to share initial dose escalation data from the Phase 1 trials of CTIM-76 and CT-95 in the second quarter of 2026 and mid-2026, respectively, (ii) our expectation to complete necessary regulatory filings to support the initiation of a first-in-human trial for CT-202 in the second quarter of 2026, (iii) having sufficient cash and cash equivalents to fund our operations into 2027, (iv) the potential benefits, characteristics, and side effect profile of our product candidates, (v) the ability of our product candidates to have benefits, characteristics, and a side effect profile that is differentiated and/or better than third party product candidates, (vi) the likelihood data will support future development, and (vii) the likelihood of obtaining regulatory approval of our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
Context Therapeutics Inc. | |||||||||||||||
Condensed Statements of Operations | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Operating Expenses | |||||||||||||||
Research and development | $ | 7,830,544 | $ | 1,384,553 | $ | 11,293,535 | $ | 3,357,762 | |||||||
General and administrative | 1,927,818 | 1,703,996 | 3,993,970 | 3,554,288 | |||||||||||
Loss from operations | (9,758,362 | ) | (3,088,549 | ) | (15,287,505 | ) | (6,912,050 | ) | |||||||
Other income | 930,852 | 834,043 | 1,882,734 | 989,747 | |||||||||||
Net loss | $ | (8,827,510 | ) | $ | (2,254,506 | ) | $ | (13,404,771 | ) | $ | (5,922,303 | ) | |||
Net loss per common share, basic and diluted | ($0.09 | ) | ($0.04 | ) | ($0.14 | ) | ($0.17 | ) | |||||||
Weighted average shares outstanding, basic and diluted | 95,186,935 | 54,958,635 | 95,186,935 | 35,462,344 | |||||||||||
Context Therapeutics Inc. | |||||||||||||||
Condensed Balance Sheets Data | |||||||||||||||
(Unaudited) | |||||||||||||||
June 30, | December 31, | ||||||||||||||
2025 | 2024 | ||||||||||||||
Cash and cash equivalents | $ | 83,517,047 | $ | 94,429,824 | |||||||||||
Other assets | 3,635,054 | 3,696,935 | |||||||||||||
Total assets | $ | 87,152,101 | $ | 98,126,759 | |||||||||||
Total liabilities | $ | 4,607,779 | $ | 2,860,497 | |||||||||||
Total stockholders' equity | 82,544,322 | 95,266,262 | |||||||||||||
Total liabilities and stockholders' equity | $ | 87,152,101 | $ | 98,126,759 | |||||||||||
Investor Relations Contact:
Jennifer Minai-Azary
Context Therapeutics
IR@contexttherapeutics.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。